Diazoxide

Cantú Syndrome: The Genetic Condition That Causes Hair Growth, and What It Means for Minoxidil

Cantu (Cantú) syndrome holds a potassium channel open, and excess hair (hypertrichosis) is there from birth. Minoxidil and diazoxide open the same family of channel.

99%
had excess body hair at birth
67 of 68 people in the Cantú registry
2 genes
ABCC9 and KCNJ8
both build the K-ATP channel minoxidil opens
about 80%
grow excess body hair on minoxidil tablets
US prescribing information, blood-pressure doses

Key takeaways

  • Cantú syndrome comes from gain-of-function variants in ABCC9 or KCNJ8, two genes that build an ATP-sensitive potassium channel. The variants leave that channel more open than normal.
  • Nearly everyone with the syndrome has excess hair from birth, and many also have heart and blood vessel features: patent ductus arteriosus, an enlarged heart, fluid around the heart.
  • Minoxidil and diazoxide open the same family of channel, and at blood-pressure doses their side effects overlap the syndrome closely enough that researchers describe it as resembling high-dose minoxidil.
  • The overlap fits the channel being minoxidil's hair target. But the variants are in every tissue from before birth, and the syndrome shows nothing about reversing pattern hair loss.
Contents8 sections

Cantú syndrome is a rare genetic condition that holds an ATP-sensitive potassium channel open in the heart, blood vessels and hair follicles. Almost everyone born with it has too much hair. Minoxidil opens the same type of channel, which is why researchers reach for Cantú syndrome as human evidence for how minoxidil grows hair.

The short answer: Cantú syndrome comes from gain-of-function variants in ABCC9 or KCNJ8, the two genes that build the ATP-sensitive potassium (K-ATP) channel minoxidil opens. In the International Cantú Syndrome Registry, 67 of 68 people (99%) had excess body hair at birth, and many had heart and blood vessel problems too (Grange et al. 2019). Hair growth, fluid around the heart and edema are also what high-dose minoxidil tablets do, which fits the channel being minoxidil's hair target. The variants are present from before birth, so none of this shows that a drug reverses pattern hair loss in adults.

What is Cantú syndrome?

Cantú syndrome, also spelled Cantu and formally called hypertrichotic osteochondrodysplasia, affects the hair, face, heart, blood vessels and skeleton. It was first described in 1982 (Ohko et al. 2020). When the gene turned up in 2012, only 33 people with it had been reported in the medical literature (Harakalova et al. 2012). The registry reported on 74 people in 2019, and nobody knows the overall incidence (Grange et al. 2019).

Hair is the visible part: 68 of 72 people (94%) reported thick scalp hair. Every person in the registry had a coarse facial appearance, including a low frontal hairline and full lips.

The heart and blood vessels make the condition serious. In the registry, 44 of 73 people (58%) had a patent ductus arteriosus, a fetal blood vessel that stays open after birth. Fluid around the heart was reported in 17 of 69 (25%), edema or lymphedema in 36 of 70 (51%), and heart failure at some point in 14%. In the subset examined at Washington University, 29 of 32 (90%) had an enlarged heart that pumped harder than normal. Developmental delay in childhood was reported in 63%, and the condition is lifelong.

The rest of this post is about what the hair growth says about a drug target. Families can find the Cantu Syndrome Interest Group, which hosts the registry at Washington University School of Medicine in St. Louis, at cantu.wustl.edu, checked on 15 November 2026.

What gene causes Cantú syndrome?

ABCC9, which encodes the channel's SUR2 subunit, came first. One 2012 team found gain-of-function variants in it in 14 of 16 patients, starting from a new variant in a child whose parents were unaffected (Harakalova et al. 2012). A second team found them in 11 of 14 (Van Bon et al. 2012).

KCNJ8, which encodes the Kir6.1 subunit, came next. One new variant, p.V65M, turned up in a patient with no ABCC9 variant (Brownstein et al. 2013). Another, p.Cys176Ser, made the channel markedly more active in cultured cells (Cooper et al. 2014). ABCC9 still accounts for most cases. Of the 74 people in the registry, 72 carried an ABCC9 variant and none carried a KCNJ8 variant (Grange et al. 2019).

A K-ATP channel is built from four pore-forming Kir6 subunits and four regulatory SUR subunits, and ATP inside the cell closes it. The discovery paper tested three Cantú variants in human embryonic kidney cells, using the heart-type pairing of Kir6.2 with SUR2A. Half the current was blocked at 0.07 mM ATP in normal channels, but took 0.28 to 1.18 mM in the variants (Harakalova et al. 2012). The variant channels stay open at ATP levels that close a normal one. The variants sit in parts of ABCC9 shared by both of its spliced forms: SUR2A in heart and skeletal muscle, SUR2B in vascular smooth muscle and hair follicles.

SUR2B is the hair one. Shorter and colleagues mapped these channels in human scalp follicles taken from non-balding skin during cosmetic surgery (Shorter et al. 2008). The dermal papilla and sheath carried SUR2B with Kir6.1, the epithelial matrix carried SUR1 with Kir6.2. In follicles from seven people in organ culture, minoxidil at 1 mM blocked the shortening of the growth phase caused by the channel blocker tolbutamide. The authors concluded that minoxidil acts only on SUR2 channels.

Is Cantú syndrome like taking minoxidil?

Clinicians spotted the resemblance before anyone knew the gene. The discovery paper cited "an unexpected phenotypic overlap between individuals with Cantú syndrome and those treated with the drug minoxidil" as one reason to think the variants open the channel (Harakalova et al. 2012). The same paper noted that minoxidil's "potent side effects of hirsutism and pericardial effusions" had "limited its use" as a blood pressure drug.

The US label for minoxidil tablets, prescribed for severe high blood pressure usually at 10 to 40 mg a day, lists several of the same features (Minoxidil Tablets 2026):

  • fine body hair lengthening, thickening and darkening in about 80% of patients, starting on the face and spreading to the back, arms, legs and scalp
  • pericardial effusion, occasionally with tamponade, in about 3% of treated patients not on dialysis
  • temporary edema in 7% of patients who were not edematous when they started
  • neonatal hypertrichosis after exposure during pregnancy

The face matches too. A 2003 case report described pseudoacromegaly, the coarse acromegaly-like features without raised growth hormone, after long-term minoxidil at an unusually high dose (Nguyen and Marks 2003). A 2013 review concluded that "most, if not all, of the effects of Cantu syndrome are replicated by high dose minoxidil, including hypertrichosis, facial dysmorphology, and pericardial effusion" (Nichols et al. 2013).

Under the microscope the hair looks like a minoxidil effect as well. Skin and hair histology in Cantú syndrome had "not been well documented" before a 2020 report of biopsies from three Japanese children with ABCC9 variants (Ohko et al. 2020). All three had more scalp follicles in the growth phase (anagen), with bulbs reaching down into the fat, thick hairs elsewhere that suggested fine vellus hairs had turned terminal, and no sebaceous glands. The authors called it "a congenital hypertrichosis due to a genetic alteration mimicking the pharmacological effect of minoxidil." Three children is a small sample, and we found no study that has looked for the missing sebaceous glands in people taking minoxidil.

Does diazoxide cause excess hair growth?

Oral diazoxide grows hair too. Its label lists "hirsutism of the lanugo type, mainly on the forehead, back and limbs" as a frequent adverse reaction (Proglycem 2026). The same label carries fluid retention, and postmarketing reports of pericardial effusion mostly in infants and children. Same family of side effects as minoxidil's. Our post on topical diazoxide for hair loss has the rest of the label and the history of putting it on the scalp.

Diazoxide hits the channel differently, though. In cloned human channels in HEK293 cells, it opened the pancreatic-type SUR1 channel fully, to 97% of the maximum reached by the reference opener NN414 (Dyhring et al. 2023). It opened SUR2B only partly, to 38% of the maximum for a different reference opener, P1075. The two percentages are not like for like. Minoxidil, for its part, has no significant reported effect on SUR1 (Davies et al. 2005). In red deer follicles in culture, five to seven animals per experiment, minoxidil raised growth at all four concentrations tested and diazoxide only at 10 µM. A SUR1-selective opener, NNC 55-0118, raised growth as well.

Pinacidil, a third K-ATP opener developed for blood pressure, fits the pattern. Upjohn researchers noted that minoxidil, pinacidil and diazoxide "have been reported to elicit hypertrichosis in humans." On the scalps of balding stumptail macaques dosed once a day for 4 to 5 months, the pinacidil analog P-1075 increased the weight of hair grown, as did minoxidil and cromakalim (Buhl et al. 1992). More on our pinacidil science page.

Does Cantú syndrome prove that minoxidil works for hair loss?

No. What it shows is that people born with an overactive K-ATP channel grow too much hair, which fits the channel driving hair growth. The evidence that minoxidil works through that channel comes from the follicle and drug-class studies above, not from the syndrome.

A Cantú variant is in the follicle, heart and blood vessels before birth, while a drug arrives decades later at levels that rise and fall. The limited evidence also suggests the two behave differently when channel activity is turned back down. On minoxidil tablets, new growth stops when the drug stops, and appearance returns to pretreatment within 1 to 6 months (Minoxidil Tablets 2026). One infant with an ABCC9 variant was given the channel blocker glibenclamide, 0.05 rising to 0.15 mg/kg a day. Edema improved within a week and a later echocardiogram showed no enlarged heart. The excess hair was not reversed after a year, which the authors suggested may be "a permanent, neonatally induced consequence" of the syndrome (Ma et al. 2019).

The mouse work is about the heart and blood vessels, not hair. Mice carrying the Cantú variants SUR2[A478V] or Kir6.1[V65M] reproduce the low blood pressure, dilated blood vessels and enlarged heart of the human condition. The paper describing them does not describe a hair or coat phenotype (Huang et al. 2018). In SUR2[A478V] mice, four weeks of glibenclamide at about 19 mg/kg a day almost completely reversed the enlarged heart and left the enlarged carotid artery unchanged (McClenaghan et al. 2020). Those authors went no further than speculating that topical K-ATP inhibitors "may be of cosmetic use for hair removal in the future."

Pattern hair loss is also a different condition. Cantú hair growth is all over the body and present at birth, while in androgenetic alopecia androgens drive scalp follicles to miniaturize into fine vellus hairs (Shorter et al. 2008). A PubMed search on 15 November 2026 found no study of whether adults with Cantú syndrome go on to develop pattern hair loss. The syndrome implicates SUR2 and Kir6.1, and says nothing either way about SUR1, the channel diazoxide shares with the pancreas. The deer follicle experiment above is the only hair study of a SUR1-selective opener we found.

What the overlap does track is the risk clinicians watch for on minoxidil tablets. At hair loss doses, usually 0.25 to 5 mg a day, a retrospective study of 1,404 patients recorded hypertrichosis in 15.1% and fluid retention in 1.3% of the 2,469 dose levels analyzed, and no pericardial disorders (Vañó-Galván et al. 2021). That study had no control group. A 2022 case report describes pericardial effusion in a previously healthy woman taking 1.25 mg a day for female pattern hair loss (Trüeb et al. 2022).

What does Cantú syndrome suggest about potassium channel drugs?

The channel does other jobs. In mice, the same one in vascular smooth muscle drives the enlarged heart (McClenaghan et al. 2020). Approval status differs drug by drug. Topical minoxidil is FDA approved for pattern hair loss. Oral minoxidil is off-label for it, and the tablet label states that using the tablets "to promote hair growth is not an approved indication" (Minoxidil Tablets 2026). Diazoxide's labelled use is low blood sugar caused by hyperinsulinism (Proglycem 2026).

The two drugs also reach the channel by different routes. Minoxidil needs activating: in cultured mouse whisker follicles, blocking sulfation stopped its effect, and minoxidil sulfate was 14 times more potent than minoxidil (Buhl et al. 1990). That step is in minoxidil sulfate vs minoxidil, and the wider mechanism case is in how minoxidil actually works. Diazoxide, applied straight to excised patches of cell membrane, activated pancreatic-type SUR1 channels and did little to cardiac SUR2A (D'hahan et al. 1999). Since it opens SUR1 fully and SUR2B only partly (Dyhring et al. 2023), the syndrome cannot tell you how much of any hair effect of diazoxide would run through either channel.

Anagen sells MINX, a compounded smooth-release oral minoxidil, and a compounded topical diazoxide. Neither is FDA approved, MINX has not been compared with immediate release minoxidil in a controlled trial, and no controlled trial has tested topical diazoxide for hair loss.

Frequently asked questions

Does Cantú syndrome cause hair loss or hair growth?

Growth. In the 2019 registry of 74 people with the syndrome, 67 of 68 had excess body hair at birth and 68 of 72 reported thick scalp hair. Whether adults with Cantú syndrome later develop pattern hair loss has not been studied, as far as we can find, so that question is open.

Is Cantú syndrome caused by minoxidil?

No. Cantú syndrome is genetic, from gain-of-function variants in ABCC9 or KCNJ8, and most cases in the international registry appear to arise as new variants in the child. Minoxidil comes up because it opens the same type of potassium channel, so its side effects at blood-pressure doses resemble the syndrome.

Is hair growth from minoxidil permanent, like in Cantú syndrome?

No. The US label for minoxidil tablets says new growth stops when the drug is stopped and appearance returns to pretreatment within 1 to 6 months. In one 2019 case report, Cantú hair looked more fixed: an infant treated for a year with the channel blocker glibenclamide still had his excess hair.

How rare is Cantú syndrome?

Very rare, and nobody knows the true incidence. When the ABCC9 gene was identified in 2012, only 33 people with the syndrome had been reported in the medical literature. By 2019 the international registry had data on 74 people, and 41% of them had first been given a different diagnosis.

Can glibenclamide treat Cantú syndrome?

Only early evidence so far. Glibenclamide is a diabetes drug that closes K-ATP channels. In Cantú syndrome mice, four weeks at about 19 mg/kg a day almost completely reversed the enlarged heart. In the one infant reported in 2019, edema improved within a week, but a year of treatment did not reverse the excess hair.

What are the side effects of oral minoxidil at hair loss doses?

In a retrospective study of 1,404 people taking low dose oral minoxidil for hair loss, with no control group, excess hair was recorded in 15.1% and fluid retention in 1.3% of the 2,469 dose levels analyzed, and no one had a pericardial disorder. A 2022 case report did describe pericardial effusion at 1.25 mg a day. Oral minoxidil is off-label for hair loss and a decision for a clinician.

References

  1. Grange DK, Roessler HI, McClenaghan C, et al. Cantú syndrome: findings from 74 patients in the International Cantú Syndrome Registry. Am J Med Genet C Semin Med Genet. 2019;181(4):658-681. DOI: 10.1002/ajmg.c.31753. PMID: 31828977Cited in Introduction · What is Cantú syndrome? · What gene causes Cantú syndrome?
  2. Ohko K, Nakajima K, Nakajima H, et al. Skin and hair abnormalities of Cantu syndrome: a congenital hypertrichosis due to a genetic alteration mimicking the pharmacological effect of minoxidil. J Dermatol. 2020;47(3):306-310. DOI: 10.1111/1346-8138.15216. PMID: 31907964Cited in What is Cantú syndrome? · Is Cantú syndrome like taking minoxidil?
  3. Harakalova M, van Harssel JJ, Terhal PA, et al. Dominant missense mutations in ABCC9 cause Cantú syndrome. Nat Genet. 2012;44(7):793-796. DOI: 10.1038/ng.2324. PMID: 22610116Cited in What is Cantú syndrome? · What gene causes Cantú syndrome? (2) · Is Cantú syndrome like taking minoxidil?
  4. Van Bon BW, Gilissen C, Grange DK, et al. Cantú syndrome is caused by mutations in ABCC9. Am J Hum Genet. 2012;90(6):1094-1101. DOI: 10.1016/j.ajhg.2012.04.014. PMID: 22608503Cited in What gene causes Cantú syndrome?
  5. Brownstein CA, Towne MC, Luquette LJ, et al. Mutation of KCNJ8 in a patient with Cantú syndrome with unique vascular abnormalities: support for the role of K(ATP) channels in this condition. Eur J Med Genet. 2013;56(12):678-682. DOI: 10.1016/j.ejmg.2013.09.009. PMID: 24176758Cited in What gene causes Cantú syndrome?
  6. Cooper PE, Reutter H, Woelfle J, et al. Cantú syndrome resulting from activating mutation in the KCNJ8 gene. Hum Mutat. 2014;35(7):809-813. DOI: 10.1002/humu.22555. PMID: 24700710Cited in What gene causes Cantú syndrome?
  7. Shorter K, Farjo NP, Picksley SM, Randall VA. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 2008;22(6):1725-1736. DOI: 10.1096/fj.07-099424. PMID: 18258787Cited in What gene causes Cantú syndrome? · Does Cantú syndrome prove that minoxidil works for hair loss?
  8. Minoxidil Tablets, USP, prescribing information (NuCare Pharmaceuticals). DailyMed, US National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bc9f21d-c959-89ee-e063-6294a90a0a62Cited in Is Cantú syndrome like taking minoxidil? · Does Cantú syndrome prove that minoxidil works for hair loss? · What does Cantú syndrome suggest about potassium channel drugs?
  9. Nguyen KH, Marks JG Jr. Pseudoacromegaly induced by the long-term use of minoxidil. J Am Acad Dermatol. 2003;48(6):962-965. DOI: 10.1067/mjd.2003.325. PMID: 12789195Cited in Is Cantú syndrome like taking minoxidil?
  10. Nichols CG, Singh GK, Grange DK. KATP channels and cardiovascular disease: suddenly a syndrome. Circ Res. 2013;112(7):1059-1072. DOI: 10.1161/CIRCRESAHA.112.300514. PMID: 23538276Cited in Is Cantú syndrome like taking minoxidil?
  11. Proglycem (diazoxide oral suspension) prescribing information, Teva Pharmaceuticals USA. DailyMed, US National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b16c7832-2fd9-49af-b923-1dc0d91fd6e2Cited in Does diazoxide cause excess hair growth? · What does Cantú syndrome suggest about potassium channel drugs?
  12. Dyhring T, Jansen-Olesen I, Christophersen P, Olesen J. Pharmacological profiling of KATP channel modulators: an outlook for new treatment opportunities for migraine. Pharmaceuticals (Basel). 2023;16(2):225. DOI: 10.3390/ph16020225. PMID: 37259373Cited in Does diazoxide cause excess hair growth? · What does Cantú syndrome suggest about potassium channel drugs?
  13. Davies GC, Thornton MJ, Jenner TJ, et al. Novel and established potassium channel openers stimulate hair growth in vitro: implications for their modes of action in hair follicles. J Invest Dermatol. 2005;124(4):686-694. DOI: 10.1111/j.0022-202X.2005.23643.x. PMID: 15816824Cited in Does diazoxide cause excess hair growth?
  14. Buhl AE, Waldon DJ, Conrad SJ, et al. Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo. J Invest Dermatol. 1992;98(3):315-319. DOI: 10.1111/1523-1747.ep12499788. PMID: 1545141Cited in Does diazoxide cause excess hair growth?
  15. Ma A, Gurnasinghani S, Kirk EP, et al. Glibenclamide treatment in a Cantú syndrome patient with a pathogenic ABCC9 gain-of-function variant: initial experience. Am J Med Genet A. 2019;179(8):1585-1590. DOI: 10.1002/ajmg.a.61200. PMID: 31175705Cited in Does Cantú syndrome prove that minoxidil works for hair loss?
  16. Huang Y, McClenaghan C, Harter TM, et al. Cardiovascular consequences of KATP overactivity in Cantu syndrome. JCI Insight. 2018;3(15):e121153. DOI: 10.1172/jci.insight.121153. PMID: 30089727Cited in Does Cantú syndrome prove that minoxidil works for hair loss?
  17. McClenaghan C, Huang Y, Yan Z, et al. Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity. J Clin Invest. 2020;130(3):1116-1121. DOI: 10.1172/JCI130571. PMID: 31821173Cited in Does Cantú syndrome prove that minoxidil works for hair loss? · What does Cantú syndrome suggest about potassium channel drugs?
  18. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. DOI: 10.1016/j.jaad.2021.02.054. PMID: 33639244Cited in Does Cantú syndrome prove that minoxidil works for hair loss?
  19. Trüeb RM, Caballero-Uribe N, Luu NC, Dmitriev A. Serious complication of low-dose oral minoxidil for hair loss. JAAD Case Rep. 2022;30:97-98. DOI: 10.1016/j.jdcr.2022.09.035. PMID: 36425662Cited in Does Cantú syndrome prove that minoxidil works for hair loss?
  20. Buhl AE, Waldon DJ, Baker CA, Johnson GA. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol. 1990;95(5):553-557. DOI: 10.1111/1523-1747.ep12504905. PMID: 2230218Cited in What does Cantú syndrome suggest about potassium channel drugs?
  21. D'hahan N, Moreau C, Prost AL, et al. Pharmacological plasticity of cardiac ATP-sensitive potassium channels toward diazoxide revealed by ADP. Proc Natl Acad Sci U S A. 1999;96(21):12162-12167. DOI: 10.1073/pnas.96.21.12162. PMID: 10518593Cited in What does Cantú syndrome suggest about potassium channel drugs?

This article is for educational purposes only and is not medical advice. Cantú syndrome is a serious genetic condition, and people who have it should be cared for by clinicians who know it. Topical minoxidil is FDA approved for pattern hair loss; oral minoxidil is used off-label for hair loss in the United States, and diazoxide is not approved for hair loss in any form. Starting, stopping or changing any prescription drug is a decision for a licensed clinician who knows your history. MINX and Anagen's topical diazoxide are compounded per prescription, and compounded drugs are not FDA approved.

Who wrote and reviewed this

Written by

Andrew Bakst

Co-founder, HairDAO

39 articles on the Anagen blog

First published
Last updated
References
21 sources

Start your personalised plan

Answer a few questions. We'll take it from there.

Take the hair assessment

Keep reading